SCHEMBL5864667

SCHEMBL5864667

COc1ccccc1Cn1c2c(c3c(OCC(=O)O)cccc31)C(C(N)=O)CCCC2

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 1/20 0.49
PLA2G2A P14555 14/20 0.48
PLA2G1B P04054 6/20 0.47
PLA2G10 O15496 3/20 0.47
PLA2G5 P39877 3/20 0.47
TSPO P30536 2/20 0.45
PLA2G2E Q9NZK7 2/20 0.43
PLA2G6 O60733 1/20 0.42
PLA2G2C Q5R387 1/20 0.42
PLA2G12B Q9BX93 1/20 0.42
PLA2G12A Q9BZM1 1/20 0.42
PLA2G2F Q9BZM2 1/20 0.42
PLA2G3 Q9NZ20 1/20 0.42
PLA2G2D Q9UNK4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5514717 0.94 PLA2G2A (0.50) FABP4PLA2G2APLA2G1BPLA2G10PLA2G5
SCHEMBL5864505 0.92 PLA2G2A (0.47) PLA2G2APLA2G1BPLA2G10PLA2G5TSPO
SCHEMBL5864665 0.92 PLA2G2A (0.51) PLA2G2APLA2G1BPLA2G10PLA2G5TSPO
SCHEMBL5864640 0.91 PLA2G2A (0.58) FABP4PLA2G2APLA2G1BPLA2G10PLA2G5
SCHEMBL5864664 0.90 PLA2G2A (0.47) FABP4PLA2G2APLA2G1BPLA2G10PLA2G5
SCHEMBL5864526 0.90 PLA2G2A (0.56) PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E
SCHEMBL5864598 0.90 FABP4 (0.48) FABP4PLA2G2APLA2G1BPLA2G10PLA2G5
SCHEMBL5864644 0.90 PLA2G2A (0.48) PLA2G2APLA2G1BPLA2G10PLA2G5TSPO
SCHEMBL5864634 0.90 PLA2G2A (0.48) FABP4PLA2G2APLA2G1BPLA2G10PLA2G5
SCHEMBL5865133 0.90 PLA2G2A (0.48) PLA2G2APLA2G1BPLA2G10PLA2G5TSPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109231-B2 Cyclohept[b]indole derivatives ELI LILLY AND COMPANY (US) 2006-09-19 US claimed
EP-1438290-B1 CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS LILLY CO ELI (US) 2005-12-14 EP claimed
US-20040198801-A1 Cyclohept'b!indole derivatives as spla2 inhibitors KINNICK MICHAEL DEAN (US) 2004-10-07 US claimed
EP-1438290-A1 CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2004-07-21 EP claimed
WO-2003016277-A1 CYCLOHEPT`B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2003-02-27 WO claimed
US-7109231-B2 Cyclohept[b]indole derivatives ELI LILLY AND COMPANY (US) 2006-09-19 US disclosed
EP-1438290-B1 CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS LILLY CO ELI (US) 2005-12-14 EP disclosed
US-20040198801-A1 Cyclohept'b!indole derivatives as spla2 inhibitors KINNICK MICHAEL DEAN (US) 2004-10-07 US disclosed
EP-1438290-A1 CYCLOHEPT B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2004-07-21 EP disclosed
WO-2003016277-A1 CYCLOHEPT`B!INDOLE DERIVATIVES AS SPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198801-A1 Cyclohept'b!indole derivatives as spla2 inhibitors SPTSSB, CPT1A, TPH2 FABP4 439/4885PLA2G2A 82/4885PLA2G1B 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.